Skip to main content
. Author manuscript; available in PMC: 2019 Sep 27.
Published in final edited form as: J Med Chem. 2018 Sep 7;61(18):8299–8320. doi: 10.1021/acs.jmedchem.8b00838

Figure 11.

Figure 11.

(A) Effects of gemcitabine (Gem), 18, and 26 on end point primary tumor volume in an orthotopic xenograft pancreatic cancer model. Mice received oral gemcitabine 75 mg/kg twice weekly or daily intraperitoneal injections of 18 or 26 (10 mg/kg) for 28 days. Data represent the mean ± SEM (n = 4 per group). (B) Number of mice with histologically confirmed liver metastases after receiving gemcitabine, 18, and 26 (n = 4 per group): (∗) p = 0.0285 vs vehicle, χ2 test.